ERBB2 and gastric cancer: Its efficacy of inhibiting proliferation and metastasis of HER2-overexpressing cells in vitro and in vivo has been proved in preclinical data together with phase I/II clinical trials in breast cancer, gastric cancer and non-small-cell lung cancer [12–15].